Progress in the treatment of chronic immune thrombocytopenia

VernacularTitle:慢性免疫性血小板减少症治疗的研究进展
Author: Wenxin OU ¹ ; Rui ZHANG ; Runhui WU ; Tianyou WANG
Author Information

1. 国家儿童医学中心　首都医科大学附属北京儿童医院　血液病中心　儿童血液病与肿瘤分子分型北京市重点实验室　儿科学国家重点学科　儿科重大疾病研究教育部重点实验室　100045
Keywords: Children; Chronic immune thrombocytopenia; Thrombopoietin; Immunosuppressive agents; Hematopoietic stem cell transplantation
From: International Journal of Pediatrics 2022;49(4):217-221
CountryChina
Language:Chinese
Abstract: Immune thrombocytopenia is a common bleeding disease characterized by isolated thrombocytopenia.Some patients last for more than 12 months and suffer from chronic immune thrombocytopenia(CITP). The pathogenesis of CITP is complex, and the traditional first-line has little improvement.In recent years, researches on second-line treatments(thrombopoietin and its receptor agonists, rituximab and splenectomy), immunosuppressive agents, all-trans retinoic acid, atorvastatin, and hematopoietic stem cell transplantation have provided new ideas for the treatment of CITP.This review summarizes the recent progress in the treatments of CITP and will be helpful for individualized treatment.